Results from Phase 1/2 Study of Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-™T) in Patients with Unresectable Locally Advanced or Metastatic Solid Tumors Refractory to Standard Therapies,

[
Results from Phase 1/2 Study of Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-™T) in Patients with Unresectable Locally Advanced or Metastatic Solid Tumors Refractory to Standard Therapies,
[og_img]
https://www.investing.com/news/press-releases/results-from-phase-12-study-of-kelunbiotechs-trop2-adc-sacituzumab-tirumotecan-sact-in-patients-with-unresectable-locally-advanced-or-metastatic-solid-tumors-refractory-to-standard-therapies-93CH-4089341


Investing.com